Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

Table 3 Diagonal linear discriminant analysis of NSCLC cell lines

			Predicted sensitivity to EGFR TKI
	Cell Line	Experimental Sensitivity to EGFR TKI (erlotinib)	Prediction based on analysis of mutational status alone (Exons 18–21)	Genomic signature/DLDA
				10-genes	50-genes	180-genes
Training	A549	No	√	√*	√	√
	UKY-29	No	√		√	√
	H1650	Yes	√	√	√	√
	PC-9	Yes	√	√	√	√
	H3255	Yes	√	√	√	√
Validation	H358	Yes		√	√	√
	H460	No	√	√	√	√
	H1975	No	√
	K562	No	√	√	√	√
	A431	Yes		√	√	√
		% Correct	80%	80%	90%	90%

Predictions of EGFR TKI sensitivity are denoted for ten cell lines used in training/validation. Column 2 demonstrates experimental sensitivity to an EGFR TKI, erlotinib (Table 1). Column 3 demonstrates prediction of sensitivity using mutational status of EGFR. Columns 4–6 denote prediction of sensitivity of the cell lines using the 10, 50, and 180 gene signatures in DLDA. √: denotes correct prediction based on experimental sensitivity to EGFR TKI. *: Leave-a-group-out cross-validation incorrectly predicts 3 of 8 replicates of this cell line.

ISSN: 1471-2164